Treatment of AGL.
D000328:Adult; D000347:Afibrinogenemia / Q000188:drug therapy; D000368:Aged; D000740:Anemia / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D006801:Humans; D006919:Hydroxyzine / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D007970:Leukopenia / Q000188:drug therapy; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011087:Polycythemia Vera / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000188:drug therapy; D013163:Splenomegaly / Q000188:drug therapy; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003561:Cytarabine; D006919:Hydroxyzine; D014750:Vincristine; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin